DNTH Historical PE Ratio Notes

— Dianthus Therapeutics (NASDAQ: DNTH) is a clinical-stage biopharmaceutical company focused on developing treatments for severe autoimmune diseases, with a strong emphasis on complement-mediated disorders such as generalized myasthenia gravis & other rare inflammatory conditions. The company’s lead candidate, DNTH103, is designed for highly selective immunomodulation, which could potentially provide best-in-class efficacy & safety profiles compared to existing therapies. For investors reviewing DNTH’s historical PE ratios, it’s important to recognize that, as a pre-commercial biotech firm, Dianthus has historically reported negative earnings due to ongoing research & development expenses & lack of revenue from product sales. This means that conventional PE ratios, which require positive earnings, are often not meaningful for much of DNTH's trading history—the ratio might be undefined, sky-high, or shown as ȁcN/Aȁd in charts and tables. Instead, fluctuations in DNTH's valuation over time have typically reflected investor expectations about the potential for future drug approvals, pipeline progress, and broader biotech sector sentiment. This context is crucial when interpreting the company’s historical price, earnings, & PE ratio data.

On this page we presented the Dianthus Therapeutics Historical PE Ratio information for Dianthus Therapeutics' stock. The average DNTH historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DNTH historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DNTH historical PE result, against the recent PE: when this page was posted on 9/4/2026, the most recent closing price for DNTH had been 108.10, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on DNTH or any other given stock, valuation analysis for DNTH can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Dianthus Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DNTH. Thanks for visiting, and the next time you need to research DNTH Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.